194 related articles for article (PubMed ID: 29251035)
1. Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease.
Handa T; Matsui S; Yoshifuji H; Kodama Y; Yamamoto H; Minamoto S; Waseda Y; Sato Y; Kubo K; Mimori T; Chiba T; Hirai T; Mishima M
Mod Rheumatol; 2018 Sep; 28(5):838-844. PubMed ID: 29251035
[TBL] [Abstract][Full Text] [Related]
2. Serum soluble interleukin-2 receptor is a useful biomarker for disease activity but not for differential diagnosis in IgG4-related disease and primary Sjögren's syndrome adults from a defined population.
Akiyama M; Sasaki T; Kaneko Y; Yasuoka H; Suzuki K; Yamaoka K; Takeuchi T
Clin Exp Rheumatol; 2018; 36 Suppl 112(3):157-164. PubMed ID: 29465360
[TBL] [Abstract][Full Text] [Related]
3. Soluble Interleukin-2 Receptor: A Potential Marker for Monitoring Disease Activity in IgG4-Related Disease.
Karim AF; Eurelings LEM; Bansie RD; van Hagen PM; van Laar JAM; Dik WA
Mediators Inflamm; 2018; 2018():6103064. PubMed ID: 29686532
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of IgG4 and soluble interleukin-2 receptor in patients with coronary artery disease.
Sakamoto A; Ishizaka N; Saito K; Imai Y; Morita H; Koike K; Kohro T; Nagai R
Clin Chim Acta; 2012 Mar; 413(5-6):577-81. PubMed ID: 22146599
[TBL] [Abstract][Full Text] [Related]
5. Association of serum IgG4 and soluble interleukin-2 receptor levels with epicardial adipose tissue and coronary artery calcification.
Sakamoto A; Ishizaka N; Imai Y; Ando J; Nagai R; Komuro I
Clin Chim Acta; 2014 Jan; 428():63-9. PubMed ID: 24482807
[TBL] [Abstract][Full Text] [Related]
6. Total lesion glycolysis as an IgG4-related disease activity marker.
Nakatsuka Y; Handa T; Nakamoto Y; Nobashi T; Yoshihuji H; Tanizawa K; Ikezoe K; Sokai A; Kubo T; Hirai T; Chin K; Togashi K; Mimori T; Mishima M
Mod Rheumatol; 2015 Jul; 25(4):579-84. PubMed ID: 25437196
[TBL] [Abstract][Full Text] [Related]
7. High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma.
Wang L; Wang JH; Liu WJ; Wang WD; Wang H; Chen XQ; Geng QR; Lu Y; Xia ZJ
Ann Hematol; 2017 Dec; 96(12):2079-2088. PubMed ID: 28871325
[TBL] [Abstract][Full Text] [Related]
8. IL-1 family cytokines and receptors in IgG4-related disease.
Capecchi R; Italiani P; Puxeddu I; Pratesi F; Tavoni A; Boraschi D; Migliorini P
Cytokine; 2018 Feb; 102():145-148. PubMed ID: 28823915
[TBL] [Abstract][Full Text] [Related]
9. Myeloid marker S100A8/A9 and lymphocyte marker, soluble interleukin 2 receptor: biomarkers of hidradenitis suppurativa disease activity?
Wieland CW; Vogl T; Ordelman A; Vloedgraven HG; Verwoolde LH; Rensen JM; Roth J; Boer J; Hessels J
Br J Dermatol; 2013 Jun; 168(6):1252-8. PubMed ID: 23320892
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6, soluble interleukin-2 receptor and soluble interleukin-6 receptor in the sera of patients with different histological patterns of rheumatoid synovitis.
Klimiuk PA; Sierakowski S; Latosiewicz R; Cylwik JP; Cylwik B; Skowronski J; Chwiecko J
Clin Exp Rheumatol; 2003; 21(1):63-9. PubMed ID: 12673891
[TBL] [Abstract][Full Text] [Related]
11. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation.
Grutters JC; Fellrath JM; Mulder L; Janssen R; van den Bosch JM; van Velzen-Blad H
Chest; 2003 Jul; 124(1):186-95. PubMed ID: 12853522
[TBL] [Abstract][Full Text] [Related]
12. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
Dejica D
Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973
[TBL] [Abstract][Full Text] [Related]
13. Distribution characteristics of elevated serum immunoglobulin G
Yang H; Li J; Wang Y; Ye S; Li J
Scand J Rheumatol; 2019 Nov; 48(6):497-504. PubMed ID: 31354076
[No Abstract] [Full Text] [Related]
14. Aspirin reduces serum anti-melanocyte antibodies and soluble interleukin-2 receptors in vitiligo patients.
Zailaie MZ
Saudi Med J; 2005 Jul; 26(7):1085-91. PubMed ID: 16047057
[TBL] [Abstract][Full Text] [Related]
15. Serum Soluble Interleukin-2 Receptor Is a Biomarker for Pneumocystis jirovecii Pneumonia among Patients with Rheumatoid Arthritis under Methotrexate Therapy.
Sakamoto N; Hara S; Ishimoto H; Nakashima S; Yura H; Miyamura T; Okuno D; Hara A; Kakugawa T; Yamaguchi H; Obase Y; Kushima H; Ishii H; Noguchi S; Kido T; Kobayashi T; Soejima Y; Yoshioka S; Ishimatsu Y; Yatera K; Kadota JI; Mukae H
Tohoku J Exp Med; 2019 Jul; 248(3):209-216. PubMed ID: 31366819
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis.
Eurelings LEM; Miedema JR; Dalm VASH; van Daele PLA; van Hagen PM; van Laar JAM; Dik WA
PLoS One; 2019; 14(10):e0223897. PubMed ID: 31622413
[TBL] [Abstract][Full Text] [Related]
17. The clinical characteristics of patients with IgG4-related disease with infiltration of the labial salivary gland by IgG4-positive cells.
Abe A; Takano K; Seki N; Jitsukawa S; Yamamoto M; Takahashi H; Himi T
Mod Rheumatol; 2014 Nov; 24(6):949-52. PubMed ID: 24670136
[TBL] [Abstract][Full Text] [Related]
18. Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity.
He L; Shu X; Liu X; Ge Y; Li S; Lu X; Wang G
Mediators Inflamm; 2020; 2020():6243019. PubMed ID: 32774147
[TBL] [Abstract][Full Text] [Related]
19. Clinical Characteristics of Patients With IgG4-Related Disease Complicated by Hypocomplementemia.
Fujita Y; Fukui S; Umeda M; Tsuji S; Iwamoto N; Nakashima Y; Horai Y; Suzuki T; Okada A; Aramaki T; Ueki Y; Mizokami A; Origuchi T; Watanabe H; Migita K; Kawakami A
Front Immunol; 2022; 13():828122. PubMed ID: 35296071
[TBL] [Abstract][Full Text] [Related]
20. Serum soluble interleukin-2 receptor in eosinophilia.
Kaito K; Otsubo H; Ogasawara Y; Kimura H; Kurihara E; Koike M; Aiso M; Kobayashi M
Acta Haematol; 2003; 109(1):23-8. PubMed ID: 12486319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
